Atai Beckley (ATAI) Stock Price, News & Analysis

Company Overview

Atai Beckley is a clinical-stage biotechnology company developing novel therapies for mental health disorders through a decentralized model of wholly owned subsidiaries and strategic collaborations. Founded in 2018 by entrepreneur Christian Angermayer, Atai Beckley focuses on addressing unmet needs in conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorders and attention-deficit/hyperactivity disorder (ADHD). The company’s approach combines psychedelic and non-psychedelic molecules alongside digital therapeutics to create differentiated treatment paradigms.

The Atai Beckley pipeline features multiple proprietary programs, including a deuterated psilocybin analog designed for enhanced stability and tolerability, an intravenous synthetic DMT administered via a patented delivery system, and novel ketamine derivatives engineered to minimize dissociative side effects. In addition, Atai Beckley has launched subsidiaries such as Perception Neuroscience, which focuses on nasal DMT delivery, and DemeRx, which develops treatments for addiction. These platform technologies are supplemented by biomarker development and patient-reported outcome tools aimed at optimizing clinical trial design and therapeutic impact.

Headquartered in Berlin, Germany, with research and development operations in North America and Europe, Atai Beckley conducts global clinical trials across multiple geographies. The company entered the public markets in 2021 through a special purpose acquisition company (SPAC) merger, providing capital to advance lead programs into late-stage studies. Atai Beckley leverages partnerships with academic institutions, contract research organizations and regulatory experts to streamline development pathways and support potential approvals in major markets.

Governed by founder Christian Angermayer and a leadership team drawn from established biopharma and academic backgrounds, Atai Beckley emphasizes robust clinical evidence and regulatory compliance. The company’s scientific advisory board includes experts in psychiatry, neurology and drug delivery, reinforcing its commitment to pioneering safe, effective treatments that could transform the standard of care for patients with chronic mental health conditions.

Key Stats

• Today's Range: $4.39 to $4.58
• 50-Day Range: $3.35 to $4.90
• 52-Week Range: $2.00 to $6.75
• Volume: 6.01 million shs
• Average Volume: 4.15 million shs
• Market Capitalization: $1.67 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Moderate Buy

Atai Beckley Stock Analysis - MarketRank™

Atai Beckley scored higher than 61% of companies evaluated by MarketBeat, and ranked 399th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atai Beckley has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Atai Beckley has a consensus price target of $16.00, representing about 253.2% upside from its current price of $4.53.

Amount of Analyst Coverage

Atai Beckley has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atai Beckley are expected to grow in the coming year, from ($0.46) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atai Beckley is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atai Beckley is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atai Beckley has a P/B Ratio of 6.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.66% of the float of Atai Beckley has been sold short.

Short Interest Ratio / Days to Cover

Atai Beckley has a short interest ratio ("days to cover") of 5.82.

Change versus previous month

Short interest in Atai Beckley has recently increased by 2.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atai Beckley does not currently pay a dividend.

Dividend Growth

Atai Beckley does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.37

News Sentiment

Atai Beckley has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Atai Beckley this week, compared to 6 articles on an average week.

Search Interest

Only 31 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

MarketBeat Follows

14 people have added Atai Beckley to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Atai Beckley insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $212,895.00 in company stock.

Percentage Held by Insiders

26.80% of the stock of Atai Beckley is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

28.41% of the stock of Atai Beckley is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/29/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• Oppenheimer CNS & Neuro-Muscular Summit: 6/10/2026
• 7th Annual HCW Neuro Perspectives Hybrid Conference: 6/15/2026
• UBS Virtual CNS Day 2026: 6/15/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATAI
• CIK: 1420529
• Web: www.ataibeckley.com
• Phone: 31 20 793 2536
• Fax: N/A
• Employees: 80
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Atai Beckley: $16.00
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +253.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$660.05 million
• Net Margins: -19,019.44%
• Pretax Margin: -5,106.46%
• Return on Equity: -89.79%
• Return on Assets: -63.58%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 7.90
• Quick Ratio: 7.90

Sales & Book Value

• Annual Sales: $4.09 million
• Price / Sales: 407.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 6.57

Miscellaneous

• Outstanding Shares: 368,170,000
• Free Float: 269,498,000
• Market Cap: $1.67 billion
• Optionable: Optionable
• Beta: 1.59